COVID-19 HAS BROAD EFFICACY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH HEART FAILURE
Ahmed Al Ansari, Khalifa Abdulrahman Yusuf, Noora Hamad Alaazmi, Dana Mohamed Awadh
This is an open access article distributed under the Creative Commons Attribution License CC BY 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Since its discovery in December 2019, the coronavirus illness (COVID-19) has spread fast over the world, affecting nearly every country. The condition, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a substantial clinical concern, overburdening healthcare systems and creating a public health risk. The prevalence of pre-existing cardiovascular illness is one of the major concerns for people infected with COVID-19. Patients with underlying heart diseases, such as chronic heart failure or coronary artery disease, had a higher risk of severe consequences and death from COVID-19, according to research. This is because of the virus’s interaction with the circulatory system, which can result in myocardial injury, cardiac arrest, and fast decompensation in severely ill individuals. Given the general population’s high prevalence of cardiovascular disease, it is critical to understand the possible impact of COVID-19 on these patients. Clinicians should give special attention to the management of patients with pre-existing cardiac disease, which should include a full re-evaluation of medication and regular monitoring of ventilation effects. The necessity of detecting and treating cardiovascular problems in COVID-19 patients cannot be emphasized. COVID-19 has become a worldwide clinical issue, and patients with pre-existing cardiovascular disorders are at a higher risk of complications and death. As a result, healthcare practitioners must be very careful in managing these patients, offering personalized care and monitoring for cardiovascular problems.